Rafinlar 75 mg Capsule 28's

Rafinlar 75 mg Capsule is an anti-cancer medicine used in the treatment of various types of cancers. Cancer is a disease caused by the abnormal growth of cells that divide uncontrollably. This medicine is used as a single agent in treating patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation. It is also used along with trametinib in treating anaplastic thyroid cancer, non-small cell lung cancer with BRAF V600E mutation, and unresectable or metastatic solid tumours with BRAF V600E mutation.

Rafinlar 75 mg Capsule contains Dabrafenib, which belongs to the class of medicines known as kinase inhibitors. It works by inhibiting the action of an enzyme (tyrosine kinase) and thus stops the abnormal growth of cancer cells.

Rafinlar 75 mg Capsule may cause certain side effects such as diarrhoea, decreased appetite, nausea, vomiting, tiredness, itching, rash, headache, fever, acne, increased blood pressure, cough, and abdominal pain. Inform your doctor if any of these side effects bother you. Rafinlar 75 mg Capsule should be taken as prescribed by your doctor. Do not take more than the recommended dose of medicine.

If you are allergic to Rafinlar 75 mg Capsule or its components, inform your doctor. Before taking Rafinlar 75 mg Capsule , inform your doctor if you have/had liver or kidney disease, calcium deficiency, heart problems, increased blood pressure, seizures, bleeding disorders, vision problems, and a history of blood clots. This medicine is known to cause embryo-fetal toxicity. It is not recommended for use in pregnancy and breastfeeding.

Rafinlar 75 mg Capsule is used in the treatment of Metastatic melanoma, Anaplastic thyroid cancer, Non-small cell lung cancer and Metastatic solid tumors. The detailed uses of Rafinlar 75 mg Capsule are as follows:

• Melanoma: Rafinlar 75 mg Capsule is used to treat unresectable or metastatic melanoma (a serious form of skin cancer) that has a BRAF V600E mutation. It may be used alone or in combination with trametinib, another targeted therapy, to improve treatment outcomes and delay disease progression.
• Non-Small Cell Lung Cancer (NSCLC): In patients with metastatic NSCLC carrying the BRAF V600E mutation, Rafinlar 75 mg Capsule is used with trametinib to help shrink tumors and manage symptoms when surgery is not an option.
• Anaplastic Thyroid Cancer: For patients with BRAF V600E-positive anaplastic thyroid cancer, which is aggressive and often inoperable, Rafinlar 75 mg Capsule (with trametinib) helps slow the spread of cancer and may improve survival.
• Low-Grade Glioma (LGG): In children aged 1 year and older, Rafinlar 75 mg Capsule is used with trametinib to treat LGG that has the BRAF V600E mutation, especially when the tumour is difficult to remove surgically or has recurred.
• Advanced Solid Tumors: Rafinlar 75 mg Capsule may also be used for BRAF V600E mutation-positive solid tumors (regardless of origin) that are advanced, have no satisfactory alternative treatments, or have progressed after prior therapies.

• Rafinlar 75 mg Capsule should be taken 1 hour before a meal or 2 hours after a meal.
• It is advised to take Rafinlar 75 mg Capsule two times a day; however, follow your doctor's advice regarding the dosage and duration.
• Swallow the capsule as a whole with a glass of water.
• Do not break, chew or crush Rafinlar 75 mg Capsule .

Rafinlar 75 mg Capsule contains Dabrafenib, which is used in treating different types of cancer. It works by stopping the action of a tyrosine kinase enzyme that causes the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body. It also decreases the blood supply to cancer tumors to slow down the growth of the tumor.  In this way, Rafinlar 75 mg Capsule stops the body's production, spread and growth of cancerous cells.

To treat your condition effectually, continue taking Rafinlar 75 mg Capsule for the period that your doctor has prescribed. Avoid taking Rafinlar 75 mg Capsule if you are allergic to it or any other components present in it. Caution should be exercised if you have/had liver or kidney disease, heart disease, blood or bleeding disorders, diabetes, eye problems, or gastrointestinal disorders. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. Avoid driving and operating machines, as this medicine may cause visual disturbances. This medicine is not recommended for use in children below six years of age as the safety and efficacy are not established. Rafinlar 75 mg Capsule may cause hypertension, thrombotic events, hemorrhagic events, cardiomyopathy, severe skin reactions, Glucose-6-phosphate Dehydrogenase Deficiency (G6PD), uveitis, tumor promotion in BRAF wild-type tumors, the occurrence of new malignancies, and hyperglycemia in some patients. Hence, inform your doctor about your complete medication and medical history before taking Rafinlar 75 mg Capsule .